文献速递血液净化与透析

血液透析合并丙型肝炎病毒感染患者的死亡率、住院率与生活质量

Mortality, Hospitalization, and Quality of Life among Patients with Hepatitis C Infection on Hemodialysis.
PubMed 文献 · Clin J Am Soc Nephrol · 2016-12-01

该研究基于透析预后与实践模式研究(DOPPS)国际前瞻性队列,纳入1996—2015年76,689例成人血液透析患者,比较丙型肝炎病毒阳性(HCV+)与阴性(HCV-)患者的死亡、住院、贫血并发症及生活质量;HCV+患者全因死亡、肝脏相关死亡、全因住院、肝脏相关住院、输血及血红蛋白<8.5 g/dl风险均升高,生活质量多项评分更差,仅1.5%接受抗病毒治疗。

要点

  • HCV+透析患者全因死亡风险升高(HR 1.12,95%CI 1.05–1.20),肝脏相关死亡风险显著升高(HR 5.90,95%CI 3.67–9.50)。
  • HCV+患者全因住院风险升高(HR 1.09,95%CI 1.04–1.13),肝脏相关住院风险显著升高(HR 4.40,95%CI 3.14–6.15)。
  • HCV+患者输血风险升高(HR 1.36,95%CI 1.20–1.55),血红蛋白<8.5 g/dl发生率升高(HR 1.12,95%CI 1.03–1.21),仅1.5%接受抗病毒药物。

核心结论

  • 血液透析患者中HCV感染与死亡、住院和贫血并发症风险升高及生活质量评分更差相关。
  • 国际上血液透析患者的HCV感染几乎从未得到治疗。
  • 作者认为该数据为在该人群中更频繁地治疗HCV提供了依据。

研究设计与样本

  • 透析预后与实践模式研究(DOPPS)为国际前瞻性队列研究,纳入血液透析患者。
  • 研究回顾了1996—2015年入组的76,689例成人患者的HCV状态。
  • 比较HCV阳性(HCV+)与HCV阴性(HCV-)患者的死亡、住院、血红蛋白浓度下降<8.5 g/dl及红细胞输注风险。
  • 使用肾脏疾病生活质量量表和流行病学研究中心简版抑郁量表比较健康相关生活质量评分。
  • 校正年龄、性别、种族、透析年限、14种合并症(包括乙型肝炎感染)及血清白蛋白、磷、肌酐浓度。

主要发现

  • 入组时7.5%的患者为HCV+。
  • HCV+血液透析患者血清丙氨酸氨基转移酶和天冬氨酸氨基转移酶未明显升高,平均浓度分别仅为22.6 U/L和21.8 U/L。
  • 中位随访1.4年。
  • HCV+ versus HCV- 的病例组合校正风险比(95%CI):全因死亡1.12(1.05–1.20),肝脏相关死亡5.90(3.67–9.50),全因住院1.09(1.04–1.13),肝脏相关住院4.40(3.14–6.15)。
  • HCV+患者身体功能、疼痛、活力、心理健康、抑郁、瘙痒和厌食生活质量评分显著更差;校正后输血风险比1.36(95%CI 1.20–1.55),血红蛋白浓度<8.5 g/dl发生率1.12(95%CI 1.03–1.21)。

临床怎么用

  • 作者认为该数据为在血液透析患者中更频繁地治疗HCV提供了依据。
  • 原文未据此给出其他推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Hepatitis C virus (HCV) infection is widely prevalent among patients on hemodialysis (HD), but very rarely treated. The aim of our study is to evaluate the burdens of HCV suffered by patients on HD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: The Dialysis Outcomes and Practice Patterns Study is an international, prospective, cohort study of patients on HD. We reviewed the HCV status of 76,689 adults enrolled between 1996 and 2015. We compared HCV-positive (HCV+) with HCV-negative (HCV-) patients for risk of mortality, hospitalization, decline in hemoglobin concentration <8.5 g/dl, and red blood cell transfusion. We also compared health-related quality of life scores using the Kidney Disease Quality of Life instrument and the Center for Epidemiologic Studies Short Depression Scale. We adjusted for age, sex, race, years on dialysis, 14 comorbid conditions (including hepatitis B infection), and serum albumin, phosphorus, and creatinine concentrations. RESULTS: A total of 7.5% of patients were HCV+ at enrollment. Serum concentrations of alanine aminotransferase and aspartate aminotransferase were not markedly elevated in HCV+ patients on HD; the mean concentrations were only 22.6 and 21.8 U/L, respectively. Median follow-up was 1.4 years. Case-mix adjusted hazard ratios (95% confidence intervals) for HCV+ versus HCV- patients were 1.12 (1.05 to 1.20) for all-cause mortality, 5.90 (3.67 to 9.50) for hepatic-related mortality, 1.09 (1.04 to 1.13) for all-cause hospitalization, and 4.40 (3.14 to 6.15) for hepatic-related hospitalization. Quality of life measures indicated significantly worse scores for physical function, pain, vitality, mental health, depression, pruritus, and anorexia among HCV+ patients. The adjusted hazard ratio for transfusion was 1.36 (95% CI, 1.20 to 1.55) and incidence of hemoglobin concentration <8.5 g/dl was 1.12 (95% CI, 1.03 to 1.21). Only 1.5% of HCV+ patients received antiviral medication. CONCLUSIONS: HCV infection among patients on HD is associated with higher risk of death, hospitalization, and anemic complications, and worse quality of life scores. Internationally, HCV infection is almost never treated in patients on HD. Our data provide a rationale for more frequent treatment of HCV in this population.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Goodkin DA, Bieber B, Jadoul M, et al. Mortality, Hospitalization, and Quality of Life among Patients with Hepatitis C Infection on Hemodialysis. Clin J Am Soc Nephrol. 2016. PMID: 27908905. doi:10.2215/CJN.07940716

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。